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SUMMARY
Background: Small bowel bacterial overgrowth is com-
mon in Crohn’s disease but its treatment is not clearly
defined. Metronidazole and ciprofloxacin are effective
antibiotics in active Crohn’s disease.
Aim: To investigate the efficacy of metronidazole and
ciprofloxacin in the treatment of bacterial overgrowth in
patients with Crohn’s disease.
Patients and methods: We performed the lactulose breath
test in 145 consecutive patients affected by Crohn’s
disease. Patients positive to the lactulose breath test
underwent a glucose breath test to confirm the over
growth. These patients were randomized in two treat-
ment groups: metronidazole 250 mg t.d.s. (Group A)
and ciprofloxacin 500 mg b.d. (Group B), both orally for
10 days. The glucose breath test was repeated at the
end of treatment. The clinical outcome after therapy
was also recorded.
Results: Bacterial overgrowth was present in 29
patients (20%). Breath test normalization occurred in
13 out of 15 patients treated by metronidazole and in all
14 patients treated by ciprofloxacin (P ¼ ns). In both
groups antibiotic treatment induced an improvement of
intestinal symptoms: bloating (Group A 85% and Group
B 83%), stool softness (44% and 50%), and abdominal
pain (50% and 43%).
Conclusions: Small bowel bacterial overgrowth is a
frequent condition in Crohn’s disease which can be
effectively treated by metronidazole or ciprofloxacin.
INTRODUCTION
The hydrogen/methane breath test has been proposed
as a sensitive and simple tool for the diagnosis of
bacterial overgrowth,1 being non-invasive and inexpen-
sive compared to a culture of intestinal aspirates and
14C-xylose breath test, respectively.2, 3 The H2 and CH4
produced in the human body after lactulose or glucose
ingestion derive entirely from intestinal bacterial
fermentation. Therefore, the appearance of an early
increase in breath H2 or CH4 concentration indicates
the presence of a small bowel bacterial overgrowth.1, 4
The lactulose breath test allows for the simultaneous
assessment of bacterial overgrowth and oro-coecal
transit time, and has been previously evaluated in
patients with Crohn’s disease.4, 5 The glucose breath
test seems to be more specific although less sensitive
than the lactulose breath test for bacterial overgrowth;
however, it does not allow for transit time assess-
ment.6, 7
Small bowel bacterial overgrowth is a frequent condi-
tion in patients affected by Crohn’s disease, particularly
in those with stenosis and entero-enteric fistula.1, 8 In a
previous study we showed by a lactulose breath test that
23% of unselected patients with Crohn’s disease pre-
sented bacterial overgrowth, and that this proportion
was even higher in patients with previous surgery.4 We
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also found that one of the possible reasons for the high
prevalence of bacterial overgrowth can be the prolonged
oro-colonic transit time, particularly in operated
subjects.4
The detection of bacterial overgrowth is important in
the clinical management of these patients because it can
contribute to the worsening of intestinal symptoms
(diarrhoea, abdominal pain and bloating) and because it
is a treatable condition in most instances.4, 9
Antibiotic therapy of bacterial overgrowth has been
studied in patients with several conditions,9–11 while
there are no specific data on treatment of bacterial
overgrowth complicating Crohn’s disease. Metronidaz-
ole and ciprofloxacin are two drugs widely used in the
treatment of active Crohn’s disease,12–14 but their
effectiveness in patients with small bowel bacterial
overgrowth is not proven.
The aim of this study was to investigate the efficacy of
metronidazole and ciprofloxacin in the treatment of
small bowel bacterial overgrowth in patients affected by
Crohn’s disease selected by the lactulose and glucose
hydrogen/methane breath test.
PATIENTS AND METHODS
From June 2000 to September 2002 we performed a
lactulose hydrogen/methane breath test in 145 eligible
consecutive patients affected by Crohn’s disease who
attended the Inflammatory Bowel Disease Clinic in our
Department. Twenty further patients were considered
ineligible because of diarrhoea and were excluded from
the study. Patients positive for bacterial overgrowth
underwent a glucose breath test in order to confirm the
result. The main characteristics of the all the subjects
are reported in Table 1.
A lactulose breath test was performed after an
overnight fast. According to Corazza et al.15 exclusion
criteria were starch ingestion in the 48 h before the test,
antibiotic treatment during the last month before the
test and diarrhoea (more than three bowel movements/
day). After the ingestion of a 100-mL water solution
containing 10 g of lactulose, breath samples were
taken at 15-min intervals for 3 h. During the test,
subjects were forbidden to eat, smoke or to exercise.
Alveolar air samples were obtained after a normal
inspiration by having the subjects exhale through a
mouthpiece into the bags connected by a three-way
valve. When the first 500 mL of expiratory air filled one
plastic bag, the end alveolar air was then collected in a
second bag (a 1–1 rubber anaesthesia bag adapted with
a one-way valve). The end alveolar air was then
transferred immediately into 50 mL plastic syringes
fitted with two-way stopcocks and was analysed within
a 2-h period.
The H2 and CH4 concentrations in breath samples
were determinated simultaneously with a Micro Lyser
DP gas chromatograph (Quintron Instrument Com-
pany, Milwaukee, WI, USA) using a molecular sieve
column (12¢Hysep Q, 60/80 mesh). Dry air was used as
the carrier gas at a flow rate of 30 mL/min. The
cromatograph was calibrated with H2 and CH4 refer-
ence mixture in compressed air (Quingas 2). Results
were expressed as parts per million (ppm) (1 ppm ¼
approximately 0.05 lmol/L for H2 and CH4). For both
gases, the smallest detectable concentration was 1 ppm,
with a linear accuracy response range of 1–150 ppm.
The presence of a small bowel bacterial overgrowth
was defined by the evidence of a peak > 20 ppm
occurring 15 min before the colonic peak. Also, patients
with an elevated fasting H2 and/or CH4 level (> 12–
15 ppm) were considered positive for bacterial over-
growth in accordance with the literature.15–18 If the
lactulose breath test was positive, a glucose breath test
was performed after 1 week to confirm the diagnosis.6, 7
The glucose breath test was performed by the admin-
istration of 50 g glucose following the same aforesaid
modalities and with the same device. The glucose breath
test was considered positive in the presence of an
increase in H2 excretion > 12 ppm over the baseline
value within 2 h. Also, an increase in H2 excretion
> 12–15 ppm in the fasting state was considered
Table 1. Characteristics of 145 patients with Crohn’s disease
Sex (M/F) 79/66
Mean age 38.6
(range) 21–70
CDAI
< 150 86
> 150 59
Localization
Ileal 71
Ileo-colonic 50
Colonic 24
Pattern
Inflammatory 60
Stricturing 55
Penetrating 30
Previous surgery 45
Data are presented as number except when indicated.
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diagnostic for bacterial overgrowth, according to the
literature.15–18
Patients with bacterial overgrowth were randomized in
two groups receiving metronidazole 250 mg t.d.s. orally
for 10 days (Group A) or ciprofloxacin 500 mg b.d.
orally for 10 days (Group B).
The randomization list to allocate the patients to
receive metronidazole or ciprofloxacin was performed by
the use of StatsDirect statistical software.
A glucose breath test was repeated 1 week after the
end of treatment.
The severity of three symptoms (pain, bloating, soft
stools) was recorded at baseline and 1 week after
antibiotics on a four-point severity scale (severe,
moderate, mild, absent), as previously described.4
Assessment was done by the patients on a visual
analogic scale with a score ranging from 0 to 3.
Statistical analysis
For categorical variables the Pearson chi-square test or
Fisher’s exact were applied as appropriate. Continuous
variables were compared with the Mann–Whitney
U-test and Wilcoxon’s sum rank test. All analyses were
two-tailed. For all analyses, probability values of 5% or
less were taken to be statistically significant. The
statistical analysis was performed using the SPSS
software package for Windows (release 11.0.1, 15
November 2001; SPSS Inc., Chicago, Ill., USA).
RESULTS
A lactulose hydrogen/methane breath test was per-
formed in 145 eligible consecutive patients affected by
Crohn’s disease attending our clinic. The mean oro-
coecal transit time was 159 ± 40, thus being longer
than those reported for the normal population of our
area (data not shown).4 The lactulose breath test was
positive for bacterial overgrowth in 30 cases. In all
positive breath tests an increase of H2 levels was seen,
while no patient showed an isolated methane peak. In
29 out of 30 patients the positive results were confirmed
at the glucose breath test. Thus, small bowel bacterial
overgrowth was present in 29 out of 145 patients with
Crohn’s disease (20%). As expected, the prevalence of
bacterial overgrowth was higher in patients with
previous surgery vs. those patients not operated upon
(33% vs. 14%: P ¼ 0.007) and in those with at least
one stricture compared to those without (29% vs. 14%:
P ¼ 0.03). Accordingly, a history of previous surgery
was present in 17 out of 29 patients with overgrowth
(58%), while at least one stricture was recognizable in
16 out of 29 of these patients (55%).
The main reported symptoms present in patients with
small bowel bacterial overgrowth were abdominal
bloating (90%), abdominal pain (48%) and soft stools
(59%).
The 29 patients with bacterial overgrowth were
randomized in two groups: Group A (15 patients)
receiving metronidazole 250 mg t.d.s. orally for 10 days
and Group B (14 patients) receiving ciprofloxacin
500 mg b.d. orally for 10 days. The characteristics of
the 29 randomized patients are reported in Table 2. Sex,
age, Crohn’s disease activity index (CDAI), localization
and pattern of disease were well distributed between the
two groups.
Treatment was well tolerated in both study groups.
One patient withdrew from metronidazole treatment
after 2 days because of nausea. No other significant
side-effects were recorded.
Glucose breath test normalization occurred in 13 out
of 15 patients treated by metronidazole and in all
patients treated by ciprofloxacin (P ¼ ns) (Figure 1). As
shown in Table 3, both antibiotic treatments induced a
significant improvement in intestinal symptom scores
compared to basal values. No significant difference in
Table 2. Characteristics of patients with bacterial overgrowth in
treatment with metronidazole 250 mg t.d.s. (Group A) or
ciprofloxacin 500 mg b.d. (Group B)
Variable
Group A
(n ¼ 15)
Group B
(n ¼ 14) P
Sex (M/F) 9/6 8/6 ns
Mean age (range) 39.5 (21–70) 38 (21–69) ns
CDAI
< 150 8 8 ns
> 150 7 6
Localization
Ileal 8 7 ns
Ileo-colonic 4 3
Colonic 3 4
Pattern
Inflammatory 3 2 ns
Stricturing 8 8
Penetrating 4 4
Previous surgery 8 7 ns
Data are presented as number except when indicated.
CDAI, Crohn’s disease activity index.
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the proportion of patients responding to therapy was
recorded between the two treatment groups, in consid-
eration of abdominal bloating (85% vs. 83%; P ¼ ns),
decrease in faecal softness (44% vs. 50%; P ¼ ns), and
abdominal pain (50% vs. 43%; P ¼ ns) (Table 4).
Both the patient resistant and one intolerant to metro-
nidazole were successfully treated by ciprofloxacin.
All patients were followed up for a median time of
16 months. The breath test has been repeated after
1 year in 20 patients. At September 2003 nine patients
have a follow up lower than 1 year. Six out of
16 patients with structuring disease had their stricture
resected. Only one patient presented a recurrence of
bacterial overgrowth 12 months after the end of
antibiotics, confirmed by the glucose breath test.
DISCUSSION
Our study confirms that small bowel bacterial over-
growth frequently complicates the course of Crohn’s
disease, thereby worsening the intestinal symptomato-
logy in many patients.
In the present study, the prevalence of small bowel
bacterial overgrowth was about 20% of patients affected
by Crohn’s disease (up to 30% in patients with previous
surgery; up to 25% in patients with strictures). These
data confirm what we have previously described in a
smaller series.4 In all patients overgrowth was identified
by H2 peak or high H2 fasting levels, while no CH4
producer was identified. The absence of CH4 producers
confirms that, at least in our area, the proportion of
methanogenic bacteria is small.4
Patients affected by this complication normally show a
worsening of abdominal pain and bloating with an
increase in faecal softness, and often it is not easy to
determine if the clinical exacerbation is due to the
primary intestinal inflammatory disease or to a secon-
dary bacterial overgrowth. In this context a hydrogen/
methane breath test can be a useful tool for the
diagnosis of this potentially treatable condition. In
addition, recent reports have highlighted the utility
and accuracy of this simple and noninvasive test for
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Figure 1. Expiratory H2 level at glucose breath test before and
after therapy with metronidazole (continuous line) and cipro-
floxacin (dotted line).
Table 3. Modification in clinical scores
induced by antibiotic therapy in 29 patients
treated with metronidazole 250 mg t.d.s.
(Group A) or ciprofloxacin 500 mg b.d.
(Group B)
Symptom
Group A (n ¼ 15) Group B (n ¼ 14)
Basal
After
treatment P Basal
After
treatment P
Bloating 2.3 ± 0.7 0.7 ± 0.9 < 0.001 2.3 ± 0.4 1.3 ± 0.4 < 0.001
Stool softness 2.3 ± 0.4 1.3 ± 0.4 0.02 1.8 ± 0.6 1.6 ± 0.5 0.04
Abdominal pain 1.8 ± 0.6 1.5 ± 0.6 0.04 1.9 ± 0.7 1.6 ± 0.5 0.04
Data are presented as mean ± standard deviation.
Table 4. Clinical response to therapy in
29 patients treated with metronidazole
250 mg t.d.s. (Group A) or ciprofloxacin
500 mg b.d. (Group B)
Symptom
Before therapy Improvement after therapy
Group A
n (%)
Group B
n (%) P
Group A
n (%)
Group B
n (%) P
Bloating 14/15 (93) 12/14 (86) ns 12/14 (85) 10/12 (83) ns
Soft stools 9/15 (60) 8/14 (57) ns 4/9 (44) 4/8 (50) ns
Abdominal pain 8/15 (53) 7/14 (50) ns 4/8 (50) 3/7 (43) ns
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detection of bowel strictures and secondary bacterial
overgrowth in patients with Crohn’s disease.8
Data on the treatment of small bowel bacterial
overgrowth complicating Crohn’s disease are scanty.
Previous reports of patients not affected by Crohn’s
disease have revealed the efficacy of antibiotics such as
norfloxacin,10 amoxicillin-clavulanate10 and rifaxi-
min11 in the treatment of bacterial overgrowth.
Metronidazole is an effective antibiotic against Gram-
negative and Gram-positive anaerobic bacteria such as
Bacterioides, Fusobacterium and peptostreptococci,19
and as such is potentially useful in the treatment of
small bowel bacterial overgrowth. On the contrary,
ciprofloxacin is not effective against anaerobic bac-
teria;20 however, it has been successfully prescribed
for intestinal decontamination in several conditions
where the Gram-negative microflora play a key
role.21, 22
Our study is the first demonstration of the efficacy of
metronidazole and ciprofloxacin in the treatment of
small bowel bacterial overgrowth in patients affected by
Crohn’s disease, even if these drugs have been widely
used in the active disease for many years.11–13
In our experience both antibiotics were effective and
well tolerated in the treatment of this condition,
although ciprofloxacin showed a small, but not statis-
tically significant, gain in terms of efficacy and tolerab-
ility compared to metronidazole.
Most patients in both study groups presented a
normalization of breath test parameters and a signifi-
cant improvement of symptoms after antibiotic treat-
ment. The most significant improvement regarded
abdominal bloating (about 80%), perhaps due to the
resolution of the small bowel bacterial over-fermenta-
tion. The other two recorded clinical symptoms
(abdominal pain, soft stools) improved in only half
the patients, probably because more symptoms related
to the underlying intestinal disease (inflammation,
strictures).
Our data suggest that a routine use of breath test may
be useful during the follow-up of patients with Crohn’s
disease in order to identify patients with bacterial
overgrowth that can be effectively treated with antibi-
otics. The main limitation of the test is the difficulties in
interpreting the results in patients with rapid transit due
to diarrhoea.15 In fact, about 12% of consecutive
patients in our series were not eligible for the test due
to the presence of diarrhoea. Furthermore, since
intestinal permeability is increased in patients with
Crohn’s disease23 it could be hypothesized that this may
account for the high incidence of a positive breath test
in this population. However, the normalization of the
breath test after antibiotics and the clinical response to
therapy seem to indicate that breath-test abnormalities
are directly related to bacterial overgrowth.
In conclusion, our paper confirms that small bowel
bacterial overgrowth is frequent in patients affected by
Crohn’s disease and that it is associated with symptoms
that can worsen patient conditions. This complication is
more frequent in patients with a history of previous
surgery and in those with stricturing pattern of disease.
Metronidazole and ciprofloxacin are both effective and
safe drugs in the treatment of this condition.
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